BofA Raises Pfizer Stock Price Target on First-Quarter Beat

Why It Matters

The upgraded target underscores renewed confidence in Pfizer’s earnings momentum, while the high dividend and valuation gap keep the stock attractive for income‑focused investors despite pipeline uncertainties.

Key Takeaways

• BofA lifts Pfizer target to $27, up $1 from prior.
• Pfizer Q1 EPS $0.75 beats $0.72 estimate.
• Revenue hit $14.5 bn, surpassing $13.84 bn forecast.
• Dividend yield remains high at 6.54%, 56‑year streak.
• Growth outlook hinges on obesity drugs and 35‑valent vaccine.

Pulse Analysis

Bank of America’s modest price‑target increase for Pfizer reflects the company’s solid first‑quarter performance, where adjusted earnings per share rose to $0.75 against a $0.72 consensus and revenue topped $14.5 billion. The beat helped sustain the stock’s price near $26.42, reinforcing its appeal amid a 6.54% dividend yield—one of the highest among large‑cap pharma peers. Analysts see the target lift as a signal that Pfizer’s near‑term earnings trajectory is better than previously modeled, even as the firm maintains a Neutral stance due to lingering growth questions.

Beyond the quarterly numbers, Pfizer’s strategic outlook hinges on two key developments. First, the firm’s long‑term growth ambition for 2028‑2033 leans heavily on its obesity‑treatment pipeline, a market segment that is becoming increasingly competitive with entrants from both biotech and big‑pharma. Second, the company disclosed a Phase‑1‑ready 35‑valent pneumococcal conjugate vaccine, a technically ambitious product that must overcome protein‑carrier suppression challenges. While the vaccine could expand Pfizer’s vaccine franchise, the lack of supportive data introduces execution risk. Additionally, the recent U.S. Vyndamax intellectual‑property settlement provides a modest boost to the fiscal 2029‑2031 outlook, but its impact is limited.

From a valuation perspective, Pfizer appears undervalued relative to its fair‑value estimates, landing it on several “most undervalued” stock lists. The combination of a robust dividend streak—56 consecutive years of payments—and a market cap near $150 billion offers a defensive cushion for investors. However, the balanced risk‑reward profile noted by BofA highlights that future catalysts, particularly around obesity drugs and the high‑valent vaccine, remain uncertain. Investors weighing income stability against growth potential will need to monitor pipeline milestones and competitive dynamics closely to gauge whether the stock can sustain its modest upside.